EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 Inhibitors

Thomas N O'Connor iD, Emily Schultz iD, Sheheryar Kabraji iD, Ellis Levine iD, Amy J Williams, Erik S Knudsen iD, Agnieszka K Witkiewicz

JCO Precision Oncology · 2026

DOI: 10.1200/po-25-00346 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JCO Precision Oncology, 2026. Verfasst von Thomas N O'Connor und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE In both the early and advanced settings, cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are approved for use in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HER2–) breast cancer (BC) in combination with endocrine therapy and increase the duration of invasive disease-free survival and progression-free survival (PFS). The duration of response to these treatments is variable between individual patients, supporting the use of biomarkers to inform treatment. Here, we investigated plasma thymidine kinase activity (TKa) as a continuous prognostic and predictive biomarker of response to CDK4/6 inhibitor–based therapy in early and advanced hormone receptor–positive/HER2– BC. MATERIALS AND METHODS TKa levels were assessed longitudinally at baseline, on treatment, and post-treatment on plasma samples from 80 metastatic and 28 high-risk patients receiving CDK4/6 inhibitor–based therapy as the standard of care. Patients were enrolled in the prospective observational Roswell Park Ciclib Study (ClinicalTrials.gov identifier: NCT04526587 ). RESULTS In the metastatic setting, TKa levels in baseline samples were inversely associated with the duration of PFS (hazard ratio, 1.91, P = .03). There was also a reduction in TKa levels from baseline to on-treatment in metastatic disease that displayed longer PFS (≥20 months; 120.7 DiviTum units of activity, DuA v 30.6 DuA, P = .028). Individuals with metastatic disease that displayed shorter PFS (≤8 months) presented with higher TKa values on treatment (220.2 DuA v 30.6 DuA, P = .008) compared with patients with longer PFS. In early-stage high-risk cases, TKa values were lower on treatment compared with baseline (41.4 DuA v 114.8 DuA, P = 3.55e-08). CONCLUSION These findings support further investigation of circulating TKa levels as a continuous prognostic and predictive biomarker of response to CDK4/6 inhibitor–based therapy. Future studies are well-suited to assess definitive TKa cutoff values to inform treatment decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsThymidine KinaseHumansFemaleMiddle AgedErb-b2 Receptor Tyrosine KinasesAgedProspective StudiesAdultBiomarkers, TumorReceptors, Estrogen

Substanzen

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsErb-b2 Receptor Tyrosine KinasesThymidine KinaseCDK4 protein, humanERBB2 protein, humanCDK6 protein, humanBiomarkers, TumorReceptors, Estrogen

Autor:innen und Institutionen

  • Department of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • Biovica International AB, San Diego, CA.

ORCID-Profile: Thomas N O'Connor, Emily Schultz, Sheheryar Kabraji, Ellis Levine, Erik S Knudsen

Förderung

  • NCI NIH HHS

Zitieren

APA

O'Connor, T. N., Schultz, E., Kabraji, S., Levine, E., Williams, A. J., Knudsen, E. S., & Witkiewicz, A. K. (2026). Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 Inhibitors. JCO Precision Oncology. https://doi.org/10.1200/po-25-00346

Vancouver

O'Connor TN, Schultz E, Kabraji S, Levine E, Williams AJ, Knudsen ES, et al. Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 Inhibitors. JCO Precision Oncology. 2026. doi:10.1200/po-25-00346

BibTeX
@article{OConnor2026,
  author = {O'Connor, Thomas N and Schultz, Emily and Kabraji, Sheheryar and Levine, Ellis and Williams, Amy J and Knudsen, Erik S and Witkiewicz, Agnieszka K},
  title = {Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 Inhibitors},
  journal = {JCO Precision Oncology},
  year = {2026},
  doi = {10.1200/po-25-00346}
}
Kostenlos starten →